An international research team, led by Israel’s Weizmann Institute of Science, has found a novel approach to tackle cancers that have become resistant to treatment. Cancer care faces a significant hurdle when therapies cease to be effective, especially in metastatic cancers where drug resistance develops due to cancer cell mutations. The team’s study, published in Cancer Discovery, suggests a new strategy to address cancer resistance by utilizing mutations that render tumors drug-resistant to fight against the cancer itself.
The researchers introduced a computational tool named SpotNeoMet, which identifies common therapy-resistant mutations generating neo-antigens, unique protein fragments present only on cancer cells. These shared neo-antigens could serve as a foundation for innovative immunotherapy methods that activate the immune system to target cancer cells selectively. Prof. Yardena Samuels at the Weizmann Institute emphasized the potential impact of this research, stating that the mutations enabling tumors to evade drugs could be exploited through precise immunotherapy to weaken the cancer.
In their experiments on metastatic prostate cancer, a condition where most patients eventually develop resistance to standard treatments, the team identified three promising neo-antigens. Unlike highly personalized therapies, this approach focuses on targeting resistance mutations common among many patients, allowing for broader application in individuals with treatment-resistant cancers.
